Table 1 Comparison of the background factors.
ETV continuation group (n = 31) | TAF switching group (n = 46) | p-value | |
|---|---|---|---|
Age (years, mean ± SD) | 54 ± 12 | 58 ± 12 | 0.15 |
Sex: Male-no. (%) | 15 (48) | 15 (33) | 0.23 |
BMI (mean ± SD) | 22 ± 4 | 23 ± 4 | 0.51 |
Genotype C-no. (%) | 31 (100) | 46 (100) | 1.00 |
ETV administration period (day, mean ± SD) | 1714 ± 785 | 2076 ± 727 | 0.13 |
HBeAg-positive-no. (%) | 3 (10) | 4 (9) | 1.00 |
HBsAg level (log IU/mL, mean ± SD) | 3.2 ± 0.5 | 3.1 ± 0.7 | 0.54 |
Change in the HBsAg level (log IU/mL/year, mean ± SD) | − 0.022 ± 0.06 | − 0.030 ± 0.06 | 0.57 |
HBcrAg level (log IU/mL, mean ± SD) | 3.7 ± 0.9 | 3.5 ± 0.7 | 0.39 |
Serum ALT (U/L, mean ± SD) | 17 ± 9 | 21 ± 12 | 0.21 |
Serum phosphate (mg/dL, mean ± SD) | 20 ± 6 | 19 ± 7 | 0.50 |
PLT (104/µL, mean ± SD) | 20 ± 6 | 18 ± 7 | 0.50 |
M2BPGi (mean ± SD) | 0.6 ± 0.3 | 1.0 ± 1.0 | 0.08 |
eGFR (mean ± SD) | 80 ± 13 | 78 ± 14 | 0.43 |
Urinary NAG/Cr | 0.04 ± 0.03 | 0.05 ± 0.03 | 0.23 |
Urinary β2MG/Cr | 2.3 ± 1.8 | 2.7 ± 4.2 | 0.31 |
Bone mineral density Lumbar vertebrae (g/cm2, mean ± SD) | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.47 |
Bone mineral density Femur (g/cm2, mean ± SD) | 0.7 ± 0.2 | 0.7 ± 0.1 | 0.36 |
